Asset
ZOVEGALISIB
RELAY THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06789913 | phase2 | recruiting | 2025-06-13 | 2031-07-01 | Relay Therapeutics, Inc. | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) |
| NCT05216432 | phase1 | recruiting | 2021-12-08 | 2027-04-30 | Relay Therapeutics, Inc. | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer |
| NCT06982521 | phase3 | recruiting | 2025-08-26 | 2028-04-30 | Relay Therapeutics, Inc. | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.